Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (111-120 of 464) with videos related to

Pageof 47
Sort By:
Clinical Drug Investigation|July 17, 2016
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy VolunteersMaria Rosario, Timothy Wyant, Timothy Leach, et al.
Clinical Therapeutics|January 27, 2020
Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative ColitisOmoniyi J Adedokun, Zhenhua Xu, Sam Liao, et al.
Nature Reviews. Gastroenterology & Hepatology|October 8, 2024
Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel diseaseChristopher Ma, Vipul Jairath, Brian G Feagan, et al.
Journal of Crohn'S & Colitis|August 4, 2023
Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE StudiesSéverine Vermeire, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 21, 2019
Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative ColitisSiddharth Singh, James A Proudfoot, Parambir S Dulai, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|October 10, 2013
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologicsShane M Devlin, Brian Bressler, Charles N Bernstein, et al.
Drugs|July 19, 2019
Innovations in Oral Therapies for Inflammatory Bowel DiseaseChristopher Ma, Robert Battat, Parambir S Dulai, et al.
Digestive Diseases and Sciences|February 28, 2018
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel DiseaseMark Fleisher, Jan Marsal, Scott D Lee, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2021
Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitisChristopher Ma, John K MacDonald, Tran M Nguyen, et al.
Current Gastroenterology Reports|March 6, 2014
Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectivesNiels Vande Casteele, Brian G Feagan, Ann Gils, et al.
Pageof 47

Showing results (111-120 of 464) with videos related to

Sort By:
Pageof 47
Clinical Drug Investigation|July 17, 2016
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy VolunteersMaria Rosario, Timothy Wyant, Timothy Leach, et al.
Clinical Therapeutics|January 27, 2020
Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative ColitisOmoniyi J Adedokun, Zhenhua Xu, Sam Liao, et al.
Nature Reviews. Gastroenterology & Hepatology|October 8, 2024
Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel diseaseChristopher Ma, Vipul Jairath, Brian G Feagan, et al.
Journal of Crohn'S & Colitis|August 4, 2023
Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE StudiesSéverine Vermeire, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 21, 2019
Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative ColitisSiddharth Singh, James A Proudfoot, Parambir S Dulai, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|October 10, 2013
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologicsShane M Devlin, Brian Bressler, Charles N Bernstein, et al.
Drugs|July 19, 2019
Innovations in Oral Therapies for Inflammatory Bowel DiseaseChristopher Ma, Robert Battat, Parambir S Dulai, et al.
Digestive Diseases and Sciences|February 28, 2018
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel DiseaseMark Fleisher, Jan Marsal, Scott D Lee, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2021
Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitisChristopher Ma, John K MacDonald, Tran M Nguyen, et al.
Current Gastroenterology Reports|March 6, 2014
Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectivesNiels Vande Casteele, Brian G Feagan, Ann Gils, et al.
Pageof 47